Published in Medical Letter on the CDC and FDA, October 16th, 2005
This randomized, double-blinded, placebo-controlled study is being conducted at approximately 12 sites in Russia, and will enroll up to 166 patients. The study's clinical endpoints are the same ones used by the U.S. Food and Drug Administration (FDA) to approve all of the presently marketed Alzheimer's disease drugs. Medivation estimates that patient dosing in this study will be completed by June 30, 2006.
Dimebon has been approved for use in Russia as an antihistamine since 1983. More recently, Dimebon was shown to bind to both...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA